DNA damage-dependent cell cycle checkpoints and genomic stability

DNA and Cell Biology

Volumn 25, Issue 7, 2006, Pages 406-411

  Ishikawa, Kazuhiro ^a   Ishii, Hideshi ^a   Saito, Toshiyuki ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL REGENERATION; CELL SURVIVAL; DNA DAMAGE; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; IONIZING RADIATION; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; GENES, CDC; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33746842309     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.406     Document Type: Article

References (61)

1. ANDERSON, L.A., and PERKINS, N.D. (2002). The large subunit of replication factor C interacts with the histone deacetylase, HDACI. J. Biol. Chem. 277, 29550-29554.
2. ARLT, M.F., XU, B., DURKIN, S.G., CASPER, A.M., KASTAN, M.B., and GLOVER, T.W. (2004). BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol. Cell. Biol. 24, 6701-6709.
3. BARTEK, J., and LUKAS, J. (2003). Chk1 and Chk2 kinases in check-point control and cancer. Cancer Cell 3, 421-429.
4. BARTEK, J., BARTKOVA, J., and LUKAS. J. (1997). The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell. Res. 237, 1-6.
5. BARTEK, J., LUKAS, C., and LUKAS, J. (2004). Checking on DNA damage in S phase. Nat. Rev. Mol. Cell. Biol. 5, 792-804.
6. BARTKOVA, J., HOREJSI, Z., KOED, K., KRAMER, A., TORT, F., ZIEGER, K., GULDBERG, P., SEHESTED, M., NESLAND, J.M., LUKAS, C., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870.
7. BASSING, C.H., SUH, H., FERGUSON, D.O., CHUA, K.F., MANIS, J., ECKERSDORFF, M., GLEASON, M., BRONSON, R., LEE, C., and ALT, F.W. (2003). Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114, 359-370.
8. BLANKLEY, R.T., and LYDALL, D. (2004). A domain of Rad9 specifically required for activation of Chk1 in budding yeast. J. Cell. Sci. 117(Pt 4), 601-608.
9. BROWN, E.J., and BALTIMORE, D. (2000). ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397-402.
10. BUSBY, E.C., LEISTRITZ, D.F., ABRAHAM, R.T., KARNITZ, L.M., and SARKARIA, J.N. (2000). The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits lhe DNA damage checkpoint kinase hChkl. Cancer Res. 60, 2108-2112.
11. CAI, R. L., YAN-NEALE, Y., CUETO, M.A., XU. H., and COHEN, D. (2000). HDACl, a histone deacetylase, forms a complex with Hus1 und Rad9, two G2/M checkpoint Rad proteins. J Biol. Chem. 275, 27909-27916.
12. CASPER, A.M.. NGHIEM, P., ARLT, M.F., and GLOVER, T.W. (2002). ATR regulates fragile site stability. Cell 111, 779-789.
13. CELESTE, A., DIFILIPPANTONIO, S., DIFILIPPANTONIO, M.J., FERNANDEZ-CAPETILLO, O., PILCH, D.R., SEDELNIKOVA, O.A., ECKHAUS, M., RIED, T., BONNER, W.M., and NUSSENZWEIG, A. (2003). H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114, 371-383.
14. DANG, T., BAO, S., and WANG, X.F. (2005). Human Rad9 is required for the activation of S-phase checkpoint and the maintenance of chromosomal stability. Genes Cell. 10, 287-295.
15. DE KLEIN, A., MUIJTJENS, M., VAN OS, R., VERHOEVEN, Y., SMIT, B., CARR, A.M., LEHMANN, A.R., and HOEIJMAKERS, J.H. (2000). Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 10, 479-482.
16. EYFJORD, J.E., and BODVARSDOTTIR, S.K. (2005). Genomic instability and cancer: Networks involved in response to DNA damage. Mutat. Res. 592, 18-28.
17. FURUYA, K., POITELEA, M., GUO, L., CASPARI, T., and CARR, A.M. (2004). Chkl activation requires Rad9 S/TQ-site phosphorylation to promote association with C-terminal BRCT domains of Rad4TOPBP1. Genes Dev. 18, 1154-1164.
18. GLOVER, T.W., and STEIN, C.K. (1988). Chromosome breakage and recombination at fragile sites. Am. J. Hum. Genet. 43, 265-273.
19. GLOVER, T.W., BERGER, C., COYLE, J., and ECHO, B. (1984). DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet. 67, 136-142.
20. GORGOULIS, V.G., VASSILIOU, L.V., KARAKAIDOS, P., ZACHARATOS, P., KOTSINAS, A., LILOGLOU, T., VENERE, M., DITULLIO, R.A., JR., KASTRINAKIS, N.G., LEVY, B., et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913.
21. GRAVES, P.R., YU, L., SCHWARZ, J.K., GALES, J., SAUSVILLE, E.A., O'CONNOR, P.M., and PIWNICA-WORMS, H. (2000). The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600-5605.
22. HANG, H., and LIEBERMAN, H.B. (2000). Physical interactions among human checkpoint control proteins HUS1p, RAD1p, and RAD9p, and implications for the regulation of cell cycle progression. Genomics 65, 24-33.
23. HIRAO, A., CHEUNG, A., DUNCAN, G., GIRARD, P.M., ELIA, A.J., WAKEHAM, A., OKADA, H., SARKISSIAN, T., WONG, J.A., SAKAI, T., et al. (2002). Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 22, 6521-6532.
24. HONG, S., PARK, S.J., KONG, H.J., SHUMAN, J.D., and CHEONG, J. (2001). Functional interaction of bZIP proteins and the large sub-unit of replication factor C in liver and adipose cells. J. Biol. Chem. 276, 28098-28105.
25. HOWLETT, N.G., TANIGUCHI, T., DURKIN, S.G., D'ANDREA, A.D., and GLOVER, T.W. (2005). The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum. Mol. Genet. 14, 693-701.
26. HUEBNER, K., and CROCE, C.M. (2001). FRA3B and other common fragile sites: The weakest link. Nat. Rev. Cancer 1, 214-221.
27. ISHII, H., INAGETA, T., MIMORI, K., SAITO, T., SASAKI, H., ISOBE, M., MORI, M., CROCE, C.M., HUEBNER, K., OZAWA, K., et al. (2005). Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis. Proc. Natl. Acad. Sci. USA. 102, 9655-9660.
28. KASTAN, M.B., and BARTEK, J. (2004). Cell-cycle checkpoints and cancer. Nature 432, 316-323.
29. KIRKIN, V., JOOS, S., and ZORNIG, M. (2004). The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644, 229-249.
30. KOMATSU, K., MIYASHITA, T., HANG, H., HOPKINS, K.M., ZHENG, W., CUDDEBACK, S., YAMADA, M., LIEBERMAN, H.B., and WANG, H.G. (2000). Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat. Cell Biol. 2, 1-6.
31. LAM, M.H., LIU, Q., ELLEDGE, S.J., and ROSEN, J.M. (2004). Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6, 45-59.
32. LIEBERMAN, H.B. (2006). Rad9, an evolutionary conserved gene with multiple functions for preserving genoniic integrity. J. Cell. Biochem. 97, 690-697.
33. LINDSEY-BOLTZ, L.A., BERMUDEZ, V.P., HURWITZ, J., and SANCAR, A. (2001). Purification and characterization of human DNA damage checkpoint Rad complexes. Proc. Natl. Acad. Sci. USA 98, 11236-11241.
34. LIU, Q., GUNTUKU, S., CUI, X.S., MATSUOKA, S., CORTEZ, D., TAMAI, K., LUO, G., CARATTINI-RIVERA, S., DEMAYO, F., BRADLEY, A., et al. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448-1459.
35. LOEGERING, D., ARLANDER. S.J., HACKBARTH, J., VROMAN, B.T., ROOS-MATTJUS, P., HOPKINS, K.M., LIEBERMAN, H.B., KARNITZ, L.M., and KAUFMANN, S.H. (2004). Rad9 protects cells from topoisomerase poison-induced cell death. J. Biol. Chem. 279, 18641-18647.
36. MAJKA, J., and BURGERS, P.M. (2004). The PCNA-RFC families of DNA clamps and clamp loaders. Prog. Nucleic Acid Res. Mol. Biol. 78, 227-260.
37. MAKINIEMI, M., HILLUKKALA, T., TUUSA, J., REINI, K., VAARA, M., HUANG, D., POSPIECH, H., MAJURI, I., WESTERLING, T., MAKELA, T.P., et al. (2001). BRCT domain-containing protein TopBP1 functions in DNA replication and damage response. J. Biol. Chem. 276, 30399-30406.
38. MATSUOKA, S., HUANG, M., and ELLEDGE, S.J. (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897.
39. MATSUOKA, S., ROTMAN, G., OGAWA, A., SHILOH, Y., TAMAI, K., and ELLEDGE, S.J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. USA 97, 10389-10394.
40. MERRICK, C.J., JACKSON, D., and DIFFLEY, J.F. (2004). Visualization of altered replication dynamics after DNA damage in human cells. J. Biol. Chem. 279, 20067-20075.
41. MUSIO, A., MONTAGNA, C., MARIANI, T., TILENNI, M., FOCARELLI, M.L., BRAIT, L., INDINO, E., BENEDETTI, P.A., CHESSA, L., ALBERTINI, A., et al. (2005). SMCI involvement in fragile site expression. Hum. Mol. Genet. 14, 525-533.
42. NYBERG, K.A., MICHELSON, R.J., PUTNAM, C.W., and WEINERT, T.A. (2002). Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 36, 617-656.
43. PARRILLA-CASTELLAR, E.R., ARLANDER, S.J., and KARNITZ, L. (2004). Dial 9-1-1 for DNA damage: The Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair (Amst) 3, 1009-1014.
44. PENNANEACH, V., SALLES-PASSADOR, I., MUNSHI, A., BRICKNER, H., REGAZZONI, K., DICK, F., DYSON, N., CHEN, T.T., WANG, J.Y., FOTEDAR, R., et al. (2001). The large subunit of replication factor C promotes cell survival after DNA damage in an LxCxE motif- and Rb-dependent manner. Mol. Cell. 7, 715-727.
45. ROOS-MATTJUS, P., HOPKINS, K.M., OESTREICH, A.J., VROMAN, B.T., JOHNSON, K.L., NAYLOR, S., LIEBERMAN, H.B., and KARNITZ, L.M. (2003). Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling. J. Biol. Chem. 278, 24428-24437.
46. SANCAR, A., LINDSEY-BOLTZ, L.A., UNSAL-KACMAZ, K., and LINN, S. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85.
47. SARKARIA, J.N., TIBBETTS, R.S., BUSBY, E.C., KENNEDY, A.P., HILL, D.E., and ABRAHAM, R.T. (1998). Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58, 4375-4382.
48. SCHWARTZ, M., ZLOTORYNSKI, E., GOLDBERG, M., OZERI, E., RAHAT, A., LE SAGE, C., CHEN, B.P., CHEN, D.J., AGAMI, R., and KEREM, B. (2005). Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev. 19, 2715-2726.
49. SHARPE, J.C., ARNOULT, D., and YOULE, R.J. (2004). Control of mitochondrial permeability by Bcl-2 family members. Biochim. Biophys. Acta 1644, 107-113.
50. SORENSEN, C.S., SYLJUASEN, R.G., LUKAS, J., and BARTEK, J. (2004). ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage. Cell Cycle 3, 941-945.
51. ST. ONGE, R.P., BESLEY, B.D., PELLEY, J.L., and DAVEY, S. (2003). A role for the phosphorylation of hRad9 in checkpoint signaling. J. Biol. Chem. 278, 26620-26628.
52. WAHL, G.M., and CARR, A.M. (2001). The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat. Cell. Biol. 3, E277-E286.
53. WALWORTH, N.C., and BERNARDS, R. (1996). rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint. Science 271, 353-356.
54. WANG, Y., CORTEZ, D., YAZDI, P., NEFF, N., ELLEDGE, S.J., and QIN, J. (2000). BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14, 927-939.
55. WU, X., SHELL, S.M., and ZOU, Y. (2005). Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with replication protein A in human cells. Oncogene 24, 4728-4735.
56. YIN, Y., ZHU, A., JIN, Y.J., LIU, Y.X., ZHANG, X., HOPKINS, K.M., and LIEBERMAN, H.B. (2004). Human RAD9 checkpoint control/proapoptotic protein can activate transcription of p21. Proc. Natl. Acad. Sci. USA 101, 8864-8869.
57. ZACHOS, G., RAINEY, M.D., and GILLESPIE, D.A. (2003). Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 22, 713-723.
58. ZHAO, H., and PIWNICA-WORMS, H. (2001). ATR-mediated check-point pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 21, 4129-4139.
59. ZLOTORYNSKI, E., RAHAT, A., SKAUG, J., BEN-PORAT, N., OZERI, E., HERSHBERG, R., LEVI, A., SCHERER, S.W., MARGALIT, H., and KEREM, B. (2003). Molecular basis for expression of common and rare fragile sites. Mol. Cell. Biol. 23, 7143-7151.
60. ZOU, L., CORTEZ, D., and ELLEDGE, S.J. (2002). Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev. 16, 198-208.
61. ZOU, L., LIU, D., and ELLEDGE, S.J. (2003). Replication protein A-mediated recruitment and activation of Rad17 complexes. Proc. Natl. Acad. Sci. USA 100, 13827-13832.